Keith G. Oldroyd

Keith G. Oldroyd

Auto-generated profile, based on publicly available information

Keith G. Oldroyd

British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in European Heart Journal
Verified
Journal Article
Closed access
UBUsman Baber
Usman Baber
GDGeorge Dangas
George Dangas
Dominick Joseph AngiolilloDominick Joseph Angiolillo
Dominick Joseph Angiolillo
DCDavid Joel Cohen
David Joel Cohen
SSSamin Kumar Sharma
Samin Kumar Sharma
RMRoxana Mehran
Roxana Mehran
Aims : The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods and results : We conducted a pre-specified subgroup analysis of The Ticagrelor With Aspirin or Alone in High Risk Patients After Coronary Intervention (TWILIGHT) trial, which enrolled 9006 patients with high-risk features undergoing PCI with DES. After 3 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin, 7119 adherent and event-free patients were randomized in a double-blind manner to ticagrelor plus placebo versus ticagrelor plus aspirin for 12 months. The primary outcome was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding while the composite of all-cause death, myocardial infarction (MI), or stroke was the key secondary outcome. Among patients with NSTE-ACS (n = 4614), ticagrelor monotherapy reduced BARC 2, 3, or 5 bleeding by 53% [3.6% vs. 7.6%; hazard ratio (HR) 0.47; 95% confidence interval (CI) 0.36–0.61; P < 0.001) and in stable patients (n = 2503) by 24% (4.8% vs. 6.2%; HR 0.76; 95% CI 0.54–1.06; P = 0.11; nominal P int = 0.03). Rates of all-cause death, MI, or stroke among those with (4.3% vs. 4.4%; HR 0.97; 95% CI 0.74–1.28; P = 0.84) and without (3.1% vs. 3.2%; HR 0.96; 95% CI 0.61–1.49; P = 0.85) NSTE-ACS were similar between treatment arms irrespective of clinical presentation (P int = 0.96). Conclusion : Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS. Trial registration: Clinicaltrials.gov identifier: NCT02270242.

19 July 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DCDamien Collison
Damien Collison
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
MAMuhammad Aetesam-Ur-Rahman
Muhammad Aetesam-Ur-Rahman
SCSamuel Copt
Samuel Copt
RMRobert McDade
Robert McDade
KOKeith G Oldroyd
Keith G Oldroyd
A fractional flow reserve (FFR) value ≥0.90 after percutaneous coronary intervention (PCI) is associated with a reduced risk of adverse cardiovascular events. TARGET-FFR is an investigator-initiated, single-centre, randomized controlled trial to determine the feasibility and efficacy of a post-PCI FFR-guided optimization strategy vs. standard coronary angiography in achieving final post-PCI FFR values ≥0.90. After angiographically guided PCI, patients were randomized 1:1 to receive a physiology-guided incremental optimization strategy (PIOS) or a blinded coronary physiology assessment (control group). The primary outcome was the proportion of patients with a final post-PCI FFR ≥0.90. Final FFR ≤0.80 was a prioritized secondary outcome. A total of 260 patients were randomized (131 to PIOS, 129 to control) and 68.1% of patients had an initial post-PCI FFR <0.90. In the PIOS group, 30.5% underwent further intervention (stent post-dilation and/or additional stenting). There was no significant difference in the primary endpoint of the proportion of patients with final post-PCI FFR ≥0.90 between groups (PIOS minus control 10%, 95% confidence interval −1.84 to 21.91, P = 0.099). The proportion of patients with a final FFR ≤0.80 was significantly reduced when compared with the angiography-guided control group (−11.2%, 95% confidence interval −21.87 to −0.35], P = 0.045). Over two-thirds of patients had a physiologically suboptimal result after angiography-guided PCI. An FFR-guided optimization strategy did not significantly increase the proportion of patients with a final FFR ≥0.90, but did reduce the proportion of patients with a final FFR ≤0.80. Findings of initial post-percutaneous coronary intervention fractional flow reserve and pullback assessments. (A) Post-percutaneous coronary intervention fractional flow reserve results following standard-of-care stenting [*238/260 (92%) with core lab-adjudicated post-percutaneous coronary intervention fractional flow reserve results available for analysis]. (B) Summary findings of 259 initial post-percutaneous coronary intervention fractional flow reserve pullback assessments (pre-randomization) demonstrating the patterns of residual disease in the study vessels. Protocol-defined targets for additional optimization measure in red bars. Multiple findings may have co-existed within individual vessels. Focal lesion defined as an abrupt pressure drop ≥0.05 fractional flow reserve units on pullback. (C) Primary endpoint—Proportion of patients with final post-percutaneous coronary intervention fractional flow reserve value ≥0.90. (D) Secondary endpoint—Proportion of patients with final post-percutaneous coronary intervention fractional flow reserve ≤0.80. Diffuse Distal, diffuse pressure gradient distal to stented segment; Diffuse Proximal, diffuse pressure gradient proximal to stented segment; Focal Distal, focal pressure drop distal to stented segment; Focal Proximal, Focal pressure drop proximal to stented segment; FFR, fractional flow reserve; HTG, hyperaemic trans-stent gradient; PCI, percutaneous coronary intervention.

1 August 2019 in Radiology
Verified
Journal Article
Open access
AIAbdul Rahman Ihdayhid
Abdul Rahman Ihdayhid
BNBjarne L. Norgaard
Bjarne L. Norgaard
SGSara Gaur
Sara Gaur
JLJonathan Leipsic
Jonathan Leipsic
NNNitesh Nerlekar
Nitesh Nerlekar
BKBrian S. Ko
Brian S. Ko
FFRCT of 0.8 or less is a predictor of long-term clinical outcomes and is superior to clinically significant stenosis on coronary CT angiograms. A normal FFRCT is associated with favorable long-ter... BackgroundCoronary CT angiography with noninvasive fractional flow reserve (FFR) predicts lesion-specific ischemia when compared with invasive FFR. The longer term prognostic value of CT-derived FF...

23 January 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TFThomas J Ford
Thomas J Ford
DCDavid Corcoran
David Corcoran
Sandosh PadmanabhanSandosh Padmanabhan
Sandosh Padmanabhan
AAAlisha Aman
Alisha Aman
PRPaul Rocchiccioli
Paul Rocchiccioli
CBColin Berry
Colin Berry
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide linked to vascular diseases through a common intronic gene enhancer [(rs9349379-G allele), chromosome 6 (PHACTR1/EDN1)]. We performed a multimodality investigation into the role of ET-1 and this gene variant in the pathogenesis of coronary microvascular dysfunction (CMD) in patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease (CAD). Three hundred and ninety-one patients with angina were enrolled. Of these, 206 (53%) with obstructive CAD were excluded leaving 185 (47%) eligible. One hundred and nine (72%) of 151 subjects who underwent invasive testing had objective evidence of CMD (COVADIS criteria). rs9349379-G allele frequency was greater than in contemporary reference genome bank control subjects [allele frequency 46% (129/280 alleles) vs. 39% (5551/14380); P = 0.013]. The G allele was associated with higher plasma serum ET-1 [least squares mean 1.59 pg/mL vs. 1.28 pg/mL; 95% confidence interval (CI) 0.10–0.53; P = 0.005]. Patients with rs9349379-G allele had over double the odds of CMD [odds ratio (OR) 2.33, 95% CI 1.10–4.96; P = 0.027]. Multimodality non-invasive testing confirmed the G allele was associated with linked impairments in myocardial perfusion on stress cardiac magnetic resonance imaging at 1.5 T (N = 107; GG 56%, AG 43%, AA 31%, P = 0.042) and exercise testing (N = 87; −3.0 units in Duke Exercise Treadmill Score; −5.8 to −0.1; P = 0.045). Endothelin-1 related vascular mechanisms were assessed ex vivo using wire myography with endothelin A receptor (ETA) antagonists including zibotentan. Subjects with rs9349379-G allele had preserved peripheral small vessel reactivity to ET-1 with high affinity of ETA antagonists. Zibotentan reversed ET-1-induced vasoconstriction independently of G allele status. We identify a novel genetic risk locus for CMD. These findings implicate ET-1 dysregulation and support the possibility of precision medicine using genetics to target oral ETA antagonist therapy in patients with microvascular angina. ClinicalTrials.gov: NCT03193294.

24 April 2019 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
NJNils P Johnson
Nils P Johnson
WLWenguang Li
Wenguang Li
XCXi Chen
Xi Chen
BHBarry Hennigan
Barry Hennigan
SWStuart Watkins
Stuart Watkins
KOKeith G Oldroyd
Keith G Oldroyd
The instantaneous wave-free ratio (iFR) and whole-cycle Pd/Pa investigate coronary physiology during non-hyperaemic conditions. To test for unique physiologic properties of the wave-free period when making resting coronary pressure measurements, we compared post hoc a diastolic pressure ratio (dPR) and Pd/Pa against iFR for numerical similarity and test/retest repeatability. Eight hundred and ninety-three lesions from 833 subjects were included from the VERIFY 2 and CONTRAST studies. Diastolic pressure ratio and a linear transform of Pd/Pa were compared against iFR for diagnostic performance. Mean difference between dPR and iFR [Δ = −0.006 ± 0.011, r2 = 0.993, area under receiver operating characteristic (ROC) curve (AUC) = 0.997] mirrored the difference of two iFR measurements repeated immediately (Δ = <0.001 ± 0.004, r2 = 0.998, AUC = 1.00). Minor variations in the definition of dPR changed its value by <1–2% over a broad range of the cardiac cycle. A linear transform of Pd/Pa showed very good diagnostic performance (Δ = −0.012 ± 0.031, r2 = 0.927, AUC = 0.979). Post hoc iFR values were validated against real-time iFR values and matched almost exactly (average Δ = <0.001 ± 0.004, 99.6% within ±0.01). Our dPR offers numerical equivalency to iFR. Despite different technical approaches for identifying the relevant period of diastole, the agreement between dPR and iFR and the insensitivity of dPR to minor variations in its definition further confirm numerical equivalency among resting metrics.

19 September 2023 in Circulation
Verified
Journal Article
Closed access
FZFrederik M. Zimmermann
Frederik M. Zimmermann
VDVictoria Y. Ding
Victoria Y. Ding
NPNico H.J. Pijls
Nico H.J. Pijls
Zsolt PiróthZsolt Piróth
Zsolt Piróth
ASAlbert H.M. van Straten
Albert H.M. van Straten
OIon behalf of the FAME 3 Investigators
on behalf of the FAME 3 Investigators
BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98–1.83]; P =0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6–1.7]; P =0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4–1.7]; P =0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1–2.7]; P =0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02100722.